<DOC>
	<DOCNO>NCT00137358</DOCNO>
	<brief_summary>Investigator since decide pursue protocol . No patient enrol . This study determine maximum tolerate dose external beam radiation para-aortic lymph node use intensity modulate radiation therapy ( IMRT ) . This protocol test hypothesis use IMRT amifostine decrease GI toxicity therefore allow radiation dose para-aortic lymph node safely escalate .</brief_summary>
	<brief_title>Radiation With Chemotherapy Study Drug Para-Aortic Nodes Cervical Cancer</brief_title>
	<detailed_description>This Phase I open-label multi-institutional study enroll minimum 27 42 patient locally advanced cervical cancer ( minimum 27 enter dose level explore without reach dose limit toxicity level ) . The primary objective determine maximum tolerate dose ( MTD ) external beam radiation para-aortic lymph node use IMRT amifostine . Patients stratify accord gross tumor volume ( GTV ) prior dose escalation . Within GTV stratum , dose escalation determine follow : Accrue 3 patient first dose level base determined stratum . A Dose Limiting Toxicity define development &gt; Grade 3 acute GI toxicity , per RTOG acute toxicity scale . If DLT observe first dose level , 3 patient enrol next dose level . If one patient experience DLT give dose level , 3 additional patient enrol dose level . If 0 3 additional patient experience DLT , dose next dose level begin . If 1 3 additional patient experience DLT high dose level maximally administer dose , dose becomes recommend dose . At least 6 patient must enter recommend dose . The Maximum Tolerated Dose ( MTD ) define dose precede 2 6 patient experience dose limit toxicity .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>No prior therapy biopsy cervix endoscopic pelvic nodal resection . Patients may endoscopic resection enlarge pelvic low common iliac node , however , needle biopsy enlarge paraaortic node eligible entry . Patients squamous cell , adenocarcinoma , adenosquamous carcinoma eligible . Patients must evidence metastatic disease outside pelvis ( except paraaortic node ) . Patients must Zubrod performance status 01 medical contraindication administration full dose chemotherapy . Patients must life expectancy &gt; 6 month Adequate bone marrow function : white blood cell ( WBC ) 3000/mm3 ( absolute neutrophil count [ ANC ] 1500/mm3 ) ; adequate renal function : creatinine 1.5 mg/dl ( urinary diversion permit improve renal function ) ; patient must bilirubin 1.5 mg/dl , ALT 2 x normal . No prior ( within last 3 year ) simultaneous malignancy ( basal cell noninvasive tumor ) Complete resection involve paraaortic node . Patients evidence bowel adherent GTV contrast enhance compute tomography ( CT ) scan ineligible . Patients follow histology ineligible : glassy cell , small cell , carcinoid , adenoid cystic , clear cell . Prior ( within last 3 year ) malignancy basal cell carcinoma noninvasive malignancy . Prior chemotherapy . Prior pelvic abdominal radiation ( transvaginal irradiation control bleed ) . Prior tumordirected surgery lymph node sampling/staging Life expectancy &lt; 6 month Patients pregnant ineligible . Patients insulin dependent diabetes ineligible . Patients obese , reliable immobilization achieve . Patients pain discomfort would preclude lie still extend period time . Patients tumor bleed require immediate treatment .</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Cervical</keyword>
	<keyword>Uterine</keyword>
	<keyword>Para-aortic</keyword>
	<keyword>Nodes</keyword>
	<keyword>IMRT</keyword>
	<keyword>Cancer</keyword>
</DOC>